Recombinant AXL (Tilvestamab Biosimilar) antibody
Quick Overview for Recombinant AXL (Tilvestamab Biosimilar) antibody (ABIN7675645)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
-
-
Expression System
- CHO Cells
-
Purpose
- Anti-AXL / UFO Reference Antibody (tilvestamab)
-
Sequence
- EVQLVESGGG LVQPGGSLRL SCAASGYSFT DFYINWVRQA PGKGLEWVAR IFPGGDNTYY NEKFKGRFTL SADTSKSTAY LQMNSLRAED TAVYYCARRG LYYAMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK,DIQMTQSPSS LSASVGDRVT ITCRSSQSLV HSNGIPYLHW YQQKPGKAPK LLIYRVSNRF SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YYCSQGTHVP PTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
-
Characteristics
- Anti-AXL / UFO Reference Antibody (tilvestamab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 146.16 kDa.
-
Purity
- >95 %
-
Isotype
- IgG1
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
Therapeutic Agents by Target and Mechanism: AXL inhibitors
Conditions: Acute myeloid leukemia
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- +4°C,-80°C
-
-
- AXL (Tilvestamab Biosimilar)
-
Target Type
- Biosimilar
-
Background
- Synonyms: UFO, ARK, TYRO7, Anexelekto, AZF
-
Molecular Weight
- 146.16 kDa
-
UniProt
- P30530
Target
-